- ABVC BioPharma Inc ABVC shares are trading higher after the FDA signed off the company's IND application for BLEX 404, the primary active ingredient in ABV-1519, for advanced inoperable or metastatic EGFR-mutated non-small cell lung cancer.
- The treatment, which is being co-developed by BioKey Inc, a wholly owned subsidiary of ABVC and Rgene Corporation, was submitted to the FDA.
- BLEX 404, the primary active ingredient, is extracted from the Maitake mushroom (Grifola frondosa), an edible mushroom.
- The immunological effects and safety have been demonstrated in two Phase 1/2 studies performed at Memorial Sloan Kettering Cancer Center with breast cancer and myelodysplastic syndromes patients.
- Price Action: ABVC shares are up 98.4% at $1.23 during the premarket session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
